<?xml version='1.0' encoding='utf-8'?>
<document id="30674264"><sentence text="Prediction of Drug-Drug Interactions Related to Inhibition or Induction of Drug-Metabolizing Enzymes." /><sentence text="Drug-drug interaction (DDI) is the phenomenon of alteration of the pharmacological activity of a drug(s) when another drug(s) is co-administered in cases of so-called polypharmacy" /><sentence text=" There are three types of DDIs: pharmacokinetic (PK), pharmacodynamic, and pharmaceutical" /><sentence text=" PK is the most frequent type of DDI, which often appears as a result of the inhibition or induction of drug-metabolising enzymes (DME)" /><sentence text=" In this review, we summarise in silico methods that may be applied for the prediction of the inhibition or induction of DMEs and describe appropriate computational methods for DDI prediction, showing the current situation and perspectives of these approaches in medicinal and pharmaceutical chemistry" /><sentence text=" We review sources of information on DDI, which can be used in pharmaceutical investigations and medicinal practice and/or for the creation of computational models" /><sentence text=" The problem of the inaccuracy and redundancy of these data are discussed" /><sentence text=" We provide information on the state-of-the-art physiologically- based pharmacokinetic modelling (PBPK) approaches and DME-based in silico methods" /><sentence text=" In the section on ligand-based methods, we describe pharmacophore models, molecular field analysis, quantitative structure-activity relationships (QSAR), and similarity analysis applied to the prediction of DDI related to the inhibition or induction of DME" /><sentence text=" In conclusion, we discuss the problems of DDI severity assessment, mention factors that influence severity, and highlight the issues, perspectives and practical using of in silico methods" /><sentence text="" /></document>